Intravitreal implant to treat uveitis launchedApril 9, 2019
Fluocinolone acetonide intravitreal implant (Yutiq) has been launched in the US, EyePoint Pharmaceuticals, Inc said. Yutiq is a three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
The company has also launched EyePoint Assist, a programme to ensure access to Yutiq for eligible patients.
One micro-insert of Yutiq has the ability to deliver up to three years of fluocinolone acetonide, a commonly used steroid, with continuous dosing that avoids the peaks and valleys of local corticosteroids, the current standard of care, the company said.
Yutiq utilizes Durasert drug delivery technology and is an intravitreal micro-insert containing 0.18 mg of fluocinolone acetonide, designed to release consistently for up to 36 months.